Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists.
Becker
Richard C
RC
Duke University School of Medicine, Durham, NC, USA. becke021@mc.duke.edu
D000818:Animals; D006470:Hemorrhage / Q000139:chemically induced / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000235:genetics*; D058925:Receptors, Purinergic P2Y12
C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058925:Receptors, Purinergic P2Y12
N Engl J Med. 2001 Aug 16;345(7):494-502
11519503
N Engl J Med. 2009 Jan 22;360(4):363-75
19106083
Lancet. 2009 Jan 24;373(9660):309-17
19108880
N Engl J Med. 2009 Jan 22;360(4):354-62
19106084
Circulation. 2009 May 19;119(19):2553-60
19414633
N Engl J Med. 2007 Nov 15;357(20):2001-15
17982182